CLINICAL TRIALS PROFILE FOR OFATUMUMAB
✉ Email this page to a colleague
All Clinical Trials for ofatumumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00349349 ↗ | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab | Completed | GlaxoSmithKline | Phase 2 | 2006-06-01 | The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab. |
| NCT00394836 ↗ | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | Completed | GlaxoSmithKline | Phase 2 | 2007-05-01 | A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy |
| NCT00410163 ↗ | Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients | Completed | GlaxoSmithKline | Phase 2 | 2007-01-01 | To investigate the safety and efficacy of two dose regimes of ofatumumab in combination with chemotherapy in previously untreated patients with B-CLL |
| NCT00494780 ↗ | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | Completed | GlaxoSmithKline | Phase 2 | 2007-06-01 | To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL) |
| NCT00603525 ↗ | Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy | Terminated | GlaxoSmithKline | Phase 3 | 2008-01-01 | This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period. The primary purpose of the study is to demonstrate the efficacy and safety of ofatumumab in reducing clinical signs and symptoms in adult RA patients who had an inadequate response to TNF-α antagonist therapy. |
| NCT00611455 ↗ | Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy | Terminated | GlaxoSmithKline | Phase 3 | 2008-01-01 | This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period. the primary purpose of the study is to demonstrate the efficacy of ofatumumab in reducing clinical signs and symptoms in adult RA patients after a single course of ofatumumab. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ofatumumab
Condition Name
Clinical Trial Locations for ofatumumab
Trials by Country
Clinical Trial Progress for ofatumumab
Clinical Trial Phase
Clinical Trial Sponsors for ofatumumab
Sponsor Name
